Local volunteers play valuable role in developing new medicines in Croydon

Posted:
21
March 2014

Richmond Pharmacology is proud to announce that its clinical trial volunteers recognise the value of the research they contribute to. The results come from recent internal polling conducted by the organisation.

The poll of 217 local volunteers, drawn from Croydon and surrounding areas, showed that over 90% were happy to continue their relationship with Richmond. Volunteers currently help to develop new medicines for some of the biggest killers, including cancer, lung disease and diabetes.

Among reasons given for their involvement, nearly a quarter of volunteers said that they had benefitted from either learning more about their medical status or enjoying the experience of the study.

Staff members were also singled out for praise. One respondent praised the some 100 local staff that work at Richmond, saying there was great team morale and the patients don't feel strange to be in a hospital and do the clinical trial.

Richmond's globally recognised clinical research facility has been based at Croydon University Hospital since 2005. Over 60% of respondents also felt that having a clinical research organisation like Richmond was beneficial to both the hospital and the local area.

Dr Jorg Taubel, founder and CEO of Richmond Pharmacology said I'm delighted by these results. Healthy volunteers and patients are the heart of what we do and I'm glad that so many want to continue contributing to the development of better and much needed novel medicines.

�We have been working closely with the people of Croydon for eight years and I'm proud that these volunteers recognize our contribution to Croydon's main hospital and the contribution we make towards the regeneration of the local area.�

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more